
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more
VJHemOnc Podcast
00:00
Treatment Updates for Chronic Lymphocytic Leukemia
The chapter delves into the latest updates on Chronic Lymphocytic Leukemia treatment, emphasizing the promising results of a specific drug with a 60% overall response rate in patients experiencing rectal transformation. It also discusses the manageable safety profile of the treatment, expected side effects, and the potential for future studies to combine the drug with other treatments.
Transcript
Play full episode